Abstract
The clinical manifestations of variability in PLWH with SARS-CoV-2 acquired may be attributed to the use of ART drugs. Omicron breakthrough infection and reinfection in 27 PLWH treated with BIC/FTC/TAF and 51 PLWH treated with TDF/3TC/EFV were investigated, and humoral and cellular immunity after Omicron breakthrough infection were also compared. The results showed that Omicron breakthrough infection symptoms in BIC/FTC/TAF-treated had a shorter duration, and BIC/FTC/TAF could further reduce the duration of symptoms when re-infected. It was also found that the BA.5 specific IgG titers of BIC/FTC/TAF-treated were significantly increased and increased with the extension of the duration of BIC/FTC/TAF. In cellular immunity, the use of BIC/FTC/TAF was also found to increase not only BA.5-specific B lymphocytes and BA.5-specific CD4+T lymphocytes, but also total CD4+T cells. In conclusion, compared to TDF/3TC/EFV, BIC/FTC/TAF can help PLWH shorten the duration of COVID-19 symptoms, enhance SARS-CoV-2 specific humoral and cellular immune responses, help to expand the total CD4+T cells increase in PLWH after Omicron infection and may be more beneficial for PLWH with high risk of infection in the context of COVID-19 normalization.